Brain Dopaminergic Signaling in Opioid Use Disorders

NCT03190954 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

153

Enrollment

NIH

Sponsor class

Conditions

Normal Physiology
Opioid Use Disorders

Interventions

DRUG: [11C]raclopride plus placebo
DRUG: [11C]raclopride plus drug
DRUG: [11C]NNC-112

Sponsor

National Institute on Alcohol Abuse and Alcoholism (NIAAA)